论文部分内容阅读
目的:探讨血清可溶性Fas/可溶性Fas配体(sFas/sFasL)水平及其与慢性乙型重症肝炎之间的关系。方法:用酶联免疫吸附双抗体夹心法检测21例无症状乙肝病毒携带者及20例慢性乙型重症肝炎患者血清sFas、sFasL水平。结果:与无症状乙肝病毒携带者比较,慢性乙型重症肝炎患者血清sFas、sFasL水平均增高,经统计学处理,均有显著性差异(P<0.01)。结论:血清sFas、sFasL水平与乙肝病毒持续感染及致重症化有关,改变血清sFasL水平可能有利于慢性乙型重症肝炎患者的预后,是一种治疗慢性乙型重症肝炎的新思路。
Objective: To investigate the relationship between serum soluble Fas / soluble Fas ligand (sFas / sFasL) and chronic severe hepatitis B (B). Methods: Serum levels of sFas and sFasL in 21 patients with asymptomatic hepatitis B virus infection and 20 patients with chronic severe hepatitis B were detected by enzyme linked immunosorbent assay (ELISA) double antibody sandwich method. Results: Compared with carriers of asymptomatic hepatitis B virus, serum sFas and sFasL levels were significantly increased in patients with chronic severe hepatitis B, which were significantly different (P <0.01). Conclusion: Serum levels of sFas and sFasL are associated with persistent infection and severe hepatitis B infection. Changing serum sFasL level may be beneficial to the prognosis of patients with chronic severe hepatitis B, which is a new way to treat chronic severe hepatitis B.